Dr. Talley on “landmark study” of investigational oral treatment for complicated UTIs
“If approved, tebipenem could provide a new oral treatment option for patients with cUTI who have limited or no alternative oral options," says Angela Talley, MD.
In this video, Angela Talley, MD, discusses next steps and the take-home message for the recent New England Journal of Medicine paper, “Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,” for which she served as senior author. Talley is senior vice president of Clinical Development at Spero Therapeutics.
Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
February 7th 2022To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
How appropriate use criteria for PSMA-PET imaging optimize patient care
February 2nd 2022In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
Dr. Padmanabhan discusses impact of COVID-19
June 11th 2020Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.
